Michael Ward

Prof Michael Ward

Associate Professor of Pharmacy

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Associate Professor Ward is Dean of Programs: Pharmacy and Medical Science. Michael's overarching philosophy is one of a connection between the foundational sciences and clinical practice. The expression of this is evident in all areas of his contribution to teaching, research, knowledge application and commitment to maintained clinical practice. His research interests are broadly focussed upon the determinants of drug response including pharmacogenetics, drug metabolism and drug interactions. Michael's background highlights the elements that underpin his philosophical approach to teaching and learning and to research. Namely, to engage with the emerging medicines and therapeutic modalities through research-acquired expertise; to remain contemporary in a complex and dynamic area of professional practice; and to accept responsibility for challenging teaching endeavours which he believes are critical for safe and effective professional practice. These three elements allow him to model explicitly the interactions between research, science-based evidence and contemporary professional practice in my teaching.

The broad focus of my research is upon the factors that influence the way in which patients respond to drug therapy. I have a particular interest in the interface between foundational sciences and clinical practice. My specific interests include;

Pharmacogenetics

Pharmacogenetics seeks to individualise drug therapy according to genetic differences between patients. This field is developing at a rapid pace and is likely to change the way in which medicine is practiced in the future. Pharmacogenetics has the potential to greatly accelerate the implementation of personalised medicine, using therapeutic regimens tailored to each individual’s genetic profile. Despite this promise and although productivity in basic pharmacogenetic research continues to escalate dramatically, harnessing this progress to achieve positive clinical outcomes poses considerable challenges. I have previously been involved in the development of provisionally patented software, SNiPPED, that facilitates multiplex genotyping with the use of denaturing high performance liquid chromatography.

Drug Metabolism and Interactions

Drug metabolism and interactions are major contributors to patient drug response. I am currently involved in a number of studies aimed at further understanding the molecular basis of drug metabolising enzyme function and of drug interactions at both a laboratory and clinical level. Laboratory based analyses involve the use of animal models including transgenic mice and isolated perfused organs. Clinical studies focus upon the impact of drug metabolism and interactions upon clinical outcomes.

Pharmacometrics

Pharmacometrics utilises computational modelling approaches to predict drug response. These models describe the relationship between drug concentrations (pharmacokinetics), mechanism of action (pharmacology), patient variables and disease characteristics to predict response to medications. Drug metabolism is an important contributor to elements of these models. Increasingly these models require the inclusion of pharmacogenetic data and understanding.

Year Citation
2025 Wong, S., Selby, P. R., Ward, M. B., & Reuter, S. E. (2025). Exploring health care professionals' engagement with a precision dosing calculator and supporting clinical information: insights from an eye-tracking and usability study. Therapeutic Drug Monitoring, online(6), 1-10.
DOI
2025 Janetzki, J., Johnson, J., Kalisch Ellett, L., Ho, J. N., Hall, K., Ward, M., & Pratt, N. (2025). Effect and illustrative costs of downscheduling on government subsidised dispensings of triptans in Australia: a 10-year analysis. Australian Health Review, 49(4, article no. AH25050), 1-7.
DOI
2025 Azroun, R., Ellett, L. K., Pratt, N., Ward, M., & Janetzki, J. (2025). National Response to Warfarin Shortages: evaluating Regulatory Substitution and Notified Shortages and Their Effects on Antithrombotic Dispensings, Pathology Monitoring and Adverse Event Trends in Australia. Drug Safety, online, 11 pages.
DOI
2025 Janetzki, J., Cornelius-Bell, A., & Ward, M. (2025). Understanding Physiotherapy student’s opinions on the importance of pharmacology and style of pharmacology assessments in preparation for future practice. Physical Therapy Reviews, 30(1), 18-27.
DOI
2025 Kalisch Ellett, L. M., Janetzki, J. L., Suppiah, V., Chai, W., Staff, K., Amato, D., . . . Ward, M. B. (2025). Quantifying the non-remunerated services provided by pharmacists in community pharmacies: a direct observational study. International Journal of Pharmacy Practice, online, 1-8.
DOI
2025 Hillen, J. B., Stanford, T., Ward, M., Duszynski, K., Tong, X., Li, S. X., . . . Pratt, N. (2025). Medicines Policy in Action: The Impact on Volume and Cost of Biologic Medicines After Biosimilar Introduction. Value in Health Regional Issues, 50(101173), 7 pages.
DOI
2025 Tan, M. S., Patel, B. K., Roughead, E. E., Ward, M., Reuter, S. E., Roberts, G., & Andrade, A. Q. (2025). Opportunities for clinical decision support targeting medication safety in remote primary care management of chronic kidney disease: a qualitative study in Northern Australia. Journal of Telemedicine and Telecare, 31(5), 656-666.
DOI
2024 Janetzki, J., Sykes, M., Ward, M., & Pratt, N. (2024). Chronic Obstructive Pulmonary Disease adverse event signals associated with potential inhibitors of glutathione peroxidase 1: a sequence symmetry analysis. Drug Safety, 47(1), 59-70.
DOI Scopus1
2024 Larcombe, R., Coulthard, K., Eaton, V., Tai, A., Reuter, S., & Ward, M. (2024). Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand. European Journal of Hospital Pharmacy, 31(4), 301-306.
DOI Scopus2 WoS2
2024 Tait, K., Gandhi, J., Ward, M., Calabretto, J. P., & Rossi, S. (2024). Student evaluation of an instructional video on how to use a national medicines information resource. International Journal of Pharmacy Practice, 32(3), 251-255.
DOI
2023 Peng, K., Blais, J. E., Pratt, N. L., Guo, J. J., Hillen, J. B., Stanford, T., . . . Li, X. (2023). Impact of introducing infliximab biosimilars on total infliximab consumption and originator infliximab prices in eight regions: an interrupted time-series analysis. BioDrugs, 37(3), 409-420.
DOI Scopus10 WoS11 Europe PMC6
2023 Janetzki, J. L., Pratt, N. L., Ward, M. B., & Sykes, M. J. (2023). Application of an integrative drug safety model for detection of adverse drug events associated with inhibition of glutathione peroxidase 1 in chronic obstructive pulmonary disease. Pharmaceutical Research, 40(6), 1553-1568.
DOI Scopus3 WoS2 Europe PMC3
2023 Wong, S., Davis, A., Selby, P. R., Khoo, R., Gwilt, I., Stocker, S. L., . . . Reuter, S. E. (2023). Application of user-centered co-design principles to address barriers in therapeutic drug monitoring.. Therapeutic drug monitoring, 45(3), 368-375.
DOI Scopus4 WoS4 Europe PMC5
2023 Tong, X., Shen, C. Y., Jeon, H. L., Li, Y., Shin, J. Y., Chan, S. C. W., . . . Lai, E. C. C. (2023). Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study. Journal Of Internal Medicine, 294(3), 314-325.
DOI Scopus17 WoS18 Europe PMC18
2022 Tong, X., Li, X., Pratt, N. L., Hillen, J. B., Stanford, T., Ward, M., . . . Wong, I. C. K. (2022). Monoclonal antibodies and Fc-fusion protein biologic medicines: a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020. Lancet Regional Health-Western Pacific, 26(100506), 1-12.
DOI Scopus19 WoS16 Europe PMC14
2022 Hillen, J., Ward, M., Slee, M., Stanford, T., Roughead, E., Kalisch Ellett, L., & Pratt, N. (2022). Utilisation of disease modifying treatment and diversity of treatment pathways in relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 57(article no. 103412), 8 pages.
DOI Scopus3 WoS3 Europe PMC3
2022 Kelly, T. L., Ward, M., Pratt, N. L., Ramsay, E., Gillam, M., & Roughead, E. E. (2022). The association between exacerbation of chronic obstructive pulmonary disease and timing of paracetamol use: a cohort study in elderly Australians. Respiratory Research, 23(1), 11 pages.
DOI Scopus3 WoS3 Europe PMC3
2022 Hillen, J. B., Stanford, T., Ward, M., Roughead, E. E., Kalisch-Ellett, L., & Pratt, N. (2022). Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database. Drugs Real World Outcomes, 9(4), 639-647.
DOI Scopus3 WoS2 Europe PMC3
2022 Putnikovic, M., Jordan, Z., Munn, Z., Borg, C., & Ward, M. (2022). Use of Electrocardiogram monitoring in adult patients taking high-risk QT interval prolonging medicines in Clinical Practice: systematic review and meta-analysis. Drug Safety, 45(10), 1037-1048.
DOI Scopus6 WoS6 Europe PMC6
2021 De Vries, C., Gadzhanova, S., Sykes, M. J., Ward, M., & Roughead, E. (2021). A systematic review and meta-analysis considering the risk for congenital heart defects of antidepressant classes and individual antidepressants. Drug Safety, 44(3), 291-312.
DOI Scopus42 WoS34 Europe PMC23
2021 Janetzki, J. L., Sykes, M. J., & Ward, M. B. (2021). Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-a sequence symmetry analysis approach. Journal of Clinical Pharmacy and Therapeutics, 46(6), 1687-1694.
DOI Scopus9 WoS6 Europe PMC6
2021 Lambert, R., Burgess, N., Hillock, N., Gailer, J., Hissaria, P., Merlin, T., . . . Hill, C. (2021). South Australian Medicines Evaluation Panel in review: providing evidence-based guidance on the use of high-cost medicines in the South Australian public health system. Australian Health Review, 45(2), 207-213.
DOI
2021 Putnikovic, M., Ward, M., & Jordan, Z. (2021). Use of ECG monitoring for adult patients taking high-risk QT interval-prolonging drugs in clinical practice: a systematic review protocol. JBI evidence synthesis, 19(11), 3113-3120.
DOI Scopus1 WoS2 Europe PMC1
2021 Reuter, S. E., Schultz, H. B., Ward, M. B., Grant, C. L., Paech, G. M., Banks, S., & Evans, A. M. (2021). The effect of high-dose, short-term caffeine intake on the renal clearance of calcium, sodium and creatinine in healthy adults. British Journal of Clinical Pharmacology, 87(11), 4461-4466.
DOI Scopus15 WoS13 Europe PMC13
2021 Menz, B., Johnson, J. L., Gillard, D. F., Chong, W., & Ward, M. B. (2021). The role of the pharmacist in optimizing cancer immunotherapy: a retrospective study of nivolumab adverse events. Journal of pharmacy practice, 34(3), 386-396.
DOI
2019 Reuter, S. E., Evans, A. M., & Ward, M. B. (2019). Reducing palivizumab dose requirements through rational dose regimen design. CPT: pharmacometrics and systems pharmacology, 8(1), 26-33.
DOI Scopus3 WoS4 Europe PMC6
2019 Eldi, P., Cooper, T., Ward, M., & Hayball, J. D. (2019). How emerging vaccine technologies are pushing disease prevention boundaries. International pharmacy journal, 37(1), 16-19.
2018 Prosser, A. E., Dawson, J. L., Koo, K., O'Kane, K. M., Ward, M. B., Woodman, R. J., . . . Phillips, C. J. (2018). Real-world incidence of patient-reported dyspnoea with ticagrelor. Therapeutic advances in drug safety, 9(10), 577-584.
DOI
2018 Caughey, G. E., Gabb, G., Ronson, S., Ward, M., Hill, C., Beukelman, T. G., & Limaye, V. (2018). Association of Statin Exposure with Histologically-Confirmed Idiopathic Inflammatory Myositis in an Australian Population. JAMA Internal Medicine, 178(9), 1224-1229.
DOI Scopus21 WoS21 Europe PMC16
2018 Petito, E. S., Foster, D. J. R., Ward, M. B., & Sykes, M. J. (2018). Molecular modeling approaches for the prediction of selected pharmacokinetic properties. Current topics in medicinal chemistry, 18(26), 2230-2238.
DOI Scopus2 WoS2 Europe PMC1
2017 Turkanovic, J., Ward, M. B., Gerber, J. P., & Milne, R. W. (2017). Effect of garlic, gingko, and St. John's wort extracts on the pharmacokinetics of fexofenadine: a mechanistic study. Drug metabolism and disposition, 45(5), 569-575.
DOI
2016 Ward, M. B., Reuter, S. E., & Martin, J. H. (2016). How 'optimal' are optimal sampling times for tyrosine kinase inhibitors in cancer? Practical considerations. Clinical pharmacokinetics, 55(10), 1171-1177.
DOI
2016 McKinnon, R. A., & Ward, M. B. (2016). Biological medicines (biologics) and biosimilars. Australian journal of pharmacy, 97(1152), 87-91.
2016 Shin, H. Y., Gadzhanova, S., Roughead, E. E., Ward, M. B., & Pont, L. G. (2016). The use of antipsychotics among people treated with medications for dementia in residential aged care facilities. International Psychogeriatrics, 28(6), 977-982.
DOI Scopus12 WoS13 Europe PMC12
2016 McKinnon, R., & Ward, M. (2016). Safety considerations of biosimilars. Australian Prescriber, 39(6), 188-189.
DOI Europe PMC6
2016 Tucker, G., DeSilva, B., Dressman, J., Ito, M., Kumamoto, T., Mager, D., . . . Ward, M. (2016). Current challenges and potential opportunities for the pharmaceutical sciences to make global impact: an FIP perspective. Journal of pharmaceutical sciences, 105(9), 2489-2497.
DOI WoS22 Europe PMC12
2015 Kershaw, S., Della Vedova, C., Majumder, I., Ward, M., Farquharson, A., Williamson, P., & White, J. (2015). Acute opioid administration induces hypothalamic-pituitary-adrenal activation and is mediated by genetic variation in interleukin (Il)1B. Pharmacology, Biochemistry and Behavior, 138, 9-13.
DOI Scopus6 WoS6 Europe PMC6
2015 Sluggett, J., Caughey, G., Ward, M., & Gilbert, A. (2015). Medicines taken by older Australians after transient ischaemic attack or ischaemic stroke: a retrospective database study. International Journal of Clinical Pharmacy, 37(5), 782-789.
DOI Scopus5 WoS3 Europe PMC3
2015 Kershaw, S. G., Dry, M., Della Vedova, C., Majumder, I., Ward, M., Williamson, P., & White, J. (2015). Inspection time as a general measure of cognitive impairment following acute opioid exposure. Drug and Alcohol Dependence, 156, e108.
DOI
2014 Westley, I., Coller, J., Ward, M., Evans, A., Morris, R., & Sallustio, B. (2014). A primer extension denaturing high-performance liquid chromatography method for the identification of three ABCC2 genetic polymorphisms. Journal of Liquid Chromatography and Related Technologies, 37(9), 1249-1256.
DOI
2014 Sluggett, J., Caughey, G., Ward, M., & Gilbert, A. (2014). Use of secondary stroke prevention medicines in Australia: National trends, 2003-2009. Medical Journal of Australia, 201(1), 54-57.
DOI Scopus7 WoS6 Europe PMC6
2014 Sluggett, J. K., Caughey, G. E., Ward, M. B., & Gilbert, A. L. (2014). Doubling the use of alteplase in Australia between 2003 and 2009. International journal of stroke, 9(6), 28.
DOI
2014 Sluggett, J., Caughey, G., Ward, M., & Gilbert, A. (2014). Antithrombotic use following transient ischaemic attack or ischaemic stroke among older Australians with atrial fibrillation. Internal Medicine Journal, 44(11), 1134-1137.
DOI Scopus1 WoS1 Europe PMC1
2013 Sluggett, J. K., Caughey, G. E., Ward, M. B., Roughead, E. E., & Gilbert, A. L. (2013). Transient ischaemic attack and ischaemic stroke : constructing episodes of care using hospital claims data. BMC research notes, 6(128), 1-6.
DOI Scopus8 Europe PMC7
2012 Dias, M., Depala, K., Ward, H., Ward, M., Sorich, M., Anderson, C., & McKinnon, R. (2012). Reforming pharmaceutical education to enhance the global uptake of pharmacogenenomics and personalized medicine. Current pharmacogenomics and personalized medicine, 10(3), 231-238.
DOI Scopus3
2012 Anderson, C., Ward, H., Corkindale, D., Ward, M., Sorich, M., & McKinnon, R. (2012). Pharmacogenomics and personalized medicine: consumer perspectives, lessons learned in Australia and beyond. Current pharmacogenomics and personalized medicine, 10(2), 170-177.
DOI Scopus1
2012 Tran, M. D., Sharley, N., & Ward, M. (2012). Stability of amoxycillin, clindamycin and meropenem in peritoneal dialysis solution. Journal of pharmacy practice and research, 42(3), 218-222.
2011 Sluggett, J. K., Ward, M. B., Caughey, G. E., & Gilbert, A. L. (2011). Pharmacotherapy for secondary prevention of transient ischaemic attack and ischaemic stroke in adults. Australian pharmacist, 30(3), 224-228.
2011 Ward, M., & Foster, D. (2011). CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualisation in H. pylori eradication. European Journal of Clinical Pharmacology, 67(3), 261-266.
DOI Scopus3 WoS3 Europe PMC3
2010 Plevin, D., Ward, H., Ward, M., Sorich, M., & McKinnon, R. (2010). Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education. American Journal of Pharmaceutical Education, 74(9), Article 168 (6 pages).
DOI Scopus6 WoS5 Europe PMC3
2010 Sorich, M., Vitry, A., Ward, M., Horowitz, J., & McKinnon, R. (2010). Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis and Haemostasis, 8(8), 1678-1684.
DOI Scopus95 WoS79 Europe PMC73
2009 Ward, M. B., Sorich, M. J., Evans, A. M., & McKinnon, R. A. (2009). Cytochrome P450 part 3: Impact of drug-drug interactions. Journal of pharmacy practice and research, 39(1), 55-58.
DOI Scopus5
2008 Ward, M. B., Sorich, M. J., & McKinnon, R. A. (2008). Cytochrome P450 Part 2: Genetics of Inter-Individual Variability. Journal of pharmacy practice and research, 38(3), 226-229.
2008 McKinnon, R. A., Sorich, M. J., & Ward, M. B. (2008). Cytochrome P450 part1: multiplicity and function. Journal of pharmacy practice and research, 38(1), 55-57.
2008 Ward, M., Kotasek, D., & McKinnon, R. (2008). Investigation of HTR3C mutations for association with 5HT3 receptor antagonist anti-emetic efficacy. Pharmagenomics, 9(8), 1027-1033.
DOI Scopus15 WoS15 Europe PMC11
2007 McKinnon, R. A., Ward, M. B., & Sorich, M. J. (2007). A critical analysis of barriers to the clinical implementation of pharmacogenomics. Therapeutics and Clinical Risk Management.

Year Citation
2021 Hillen, J., Ward, M., Slee, M., Stanford, T., Roughead, E. E., Kalisch-Ellett, L., & Pratt, N. (2021). Utilisation and treatment patterns of medicines to manage relapsing remitting multiple sclerosis: Implications for pharmacovigilance. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY Vol. 30 (pp. 390). WILEY.
2012 Sluggett, J. K., Caughey, G. E., Ward, M. B., & Gilbert, A. L. (2012). Drug Treatment after Transient ischaemic Attack or Ischaemic Stroke: Are We Doing Enough to Reduce Secondary Risk?. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY Vol. 21 (pp. 29). WILEY PERIODICALS, INC.

Year Citation
2016 Caughey, G. E., Gabb, G. M., Ronson, S., Ward, M., Hill, C. L., & Limaye, V. (2016). Association of Idiopathic Inflammatory Myositis with Statin Exposure: A Population Based Case Control Study. Poster session presented at the meeting of PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. WILEY-BLACKWELL.
2014 Sluggett, J. K., Caughey, G. E., Ward, M. B., & Gilbert, A. L. (2014). Health Outcomes for Older Australians After Transient Ischaemic Attack (TIA) or Ischaemic Stroke (IS). Poster session presented at the meeting of PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. WILEY-BLACKWELL.

Year Citation
2021 Ward, M., Reuter Lange, S., & Staff, K. (2021). International biosimilar medicines catalogue and summary of published literature: quarterly update October-December 2020. Australia: GBMA Education.
2020 Ward, M., Reuter Lange, S., & Staff, K. (2020). International biosimilar medicines review of the literature: quarterly update January 2020 - March 2020. Australia: GBMA Education.
2020 Ward, M., Reuter Lange, S., & Staff, K. (2020). International biosimilar medicines review of the literature: quarterly update October 2019 - December 2019. Australia: GBMA Education.
2020 Ward, M., Reuter Lange, S., & Staff, K. (2020). International biosimilar medicines: catalogue and summary of published literature: quarterly update April 2020 - June 2020. Australia: GBMA Education, Australia.
2020 Ward, M., Reuter Lange, S., & Staff, K. (2020). International biosimilar medicines review of the literature: quarterly update: quarterly update July-September 2020. Australia: GBMA Education.
2019 Ward, M., Reuter Lange, S., & Staff, K. (2019). International biosimilar medicines review of the literature: quarterly update July 2019 - September 2019. Australia: GBMA Education.
2019 Ward, M., Reuter Lange, S., & Staff, K. (2019). International biosimilar medicines review of the literature: quarterly update April 2019 - June 2019. Australia: GBMA Education.
2019 Ward, M., Reuter Lange, S., & Staff, K. (2019). International biosimilar medicines review of the literature: quarterly update January 2019 - March 2019. Australia: GBMA Education.
2019 Ward, M., Reuter Lange, S., & Staff, K. (2019). International biosimilar medicines review of the literature: quarterly update June 2018 - September 2018. Australia: GBMA Education.
2018 Ward, M., Reuter Lange, S., & Staff, K. (2018). International biosimilar medicines review of the literature: quarterly update October 2018 - December 2018. Australia: GBMA Education.
2018 Ward, M., Reuter Lange, S., & Staff, K. (2018). Literature review of international biosimilar medicines: update December 2017 - February 2018. Australia: Commonwealth of Australia as represented by the Department of Health.
2018 Ward, M., Reuter Lange, S., & Staff, K. (2018). Literature review of international biosimilar medicines: update March - May 2018. Australia: Commonwealth of Australia as represented by the Department of Health.
2017 Ward, M., Reuter Lange, S., & Staff, K. (2017). Literature review of international biosimilar medicines: update March - May 2017. Australia: Commonwealth of Australia as represented by the Department of Health.
2017 Ward, M., Reuter Lange, S., & Staff, K. (2017). Literature review of international biosimilar medicines: update September - November 2017. Australia: Commonwealth of Australia as represented by the Department of Health.
2017 Ward, M., Reuter Lange, S., & Staff, K. (2017). Literature review of international biosimilar medicines: update December 2016 - March 2017. Australia: Commonwealth of Australia as represented by the Department of Health.
2017 Ward, M., Reuter Lange, S., & Staff, K. (2017). Literature review of international biosimilar medicines: update June - August 2017. Australia: Commonwealth of Australia as represented by the Department of Health.
2016 Ward, M., Reuter Lange, S., & Staff, K. (2016). Literature review of international biosimilar medicines: update September - December 2016. Australia: Commonwealth of Australia as represented by the Department of Health.
2016 Ward, M., Reuter Lange, S., & Staff, K. (2016). Literature review of International Biosimilar Medicines: Update June - September 2016. Australia: Commonwealth of Australia as represented by the Department of Health.
2016 Ward, M., Reuter Lange, S., & Staff, K. (2016). Literature review of international biosimilar medicines. Australia: Commonwealth of Australia as represented by the Department of Health.
  • Large scale evidence generation for the utilisation and safety of biologic medicines, NHMRC - Project Grant, 01/01/2019 - 31/12/2023

  • Literature Review of International Biosimilar Medicines, Cwth Dept of Health Aged Care, 01/03/2016 - 30/06/2018

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Mr Aaron Matthew Kinnear
2024 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Mr Brett Ritchie
2018 Principal Supervisor - Doctor of Philosophy Doctorate Full Time Ms Rebecca Larcombe
2018 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Emilio Petito
2016 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Miss Courtney Elise De Vries

Connect With Me

External Profiles

Other Links